Effects of adding intrathecal neostigmine or magnesium sulphate to bupivacaine in patients under lower extremities surgeries.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012071910336N1

Enrollment

Registered

2012-08-15

Start date

2010-02-24

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contusion of other and unspecified parts of foot. Contusion of other and unspecified parts of foot

Interventions

Intervention 1: magnesium sulphate 50% Pasteur Institute, Tehran, Iran, singel dose Intrathecal. Intervention 2: neostigmine 0.5 mg/ml (1 ml) Caspian Tamin Co. Rasht, Iran singel dose Intrathecal. Int

Treatment - Drugs

magnesium sulphate 50% Pasteur Institute, Tehran, Iran, singel dose Intrathecal.

neostigmine 0.5 mg/ml (1 ml) Caspian Tamin Co. Rasht, Iran singel dose Intrathecal.

Bupivacaine 0.5% intrathecal injection(Astra-Zeneca)

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:The inclusion criteria were patients between 20-65 years who were candidates for lower extremity surgeries and signed informed consent. Exclusion criteria: local infection; hemorrhagic disorders; drug hypersensitivity; muscular disorders ; central and peripheral neuropathy; drug abuse history and addiction.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sensory block onset. Timepoint: Every 30 second. Method of measurement: Second.	—

Secondary

Measure	Time frame
Recovery of sensory block. Timepoint: Every 5 minute. Method of measurement: Minute.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Reza Feiz

Tehran University Of Medical Sceinces

hrfeiz@hotmail.com+98 21 6435

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026